OTCM
YBGJ
, Last price
USD
Name
Yubo International Biotech Ltd
Chart & performance
P/E
—
P/B
—
EPS
—
Vol. 1Y
—
Shs. 5Y
159.84%
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
134k
+3,772.94%
Net income
-1m
L-39.21%
CFO
-843k
L-37.00%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Yubo International Biotech Limited, operating through its various subsidiaries, primarily dedicates its efforts to the research, development, and practical application of endometrial stem cells. Beyond this core focus, the company also provides a diverse range of products, including solutions for respiratory health, skincare and hair care formulations, nutritious beverages, and personal care items tailored for both men and women. Furthermore, it delivers specialized stem cell services, such as cellular analysis and comprehensive health management consulting, all offered under the VIVCELL brand. The company's headquarters are located in Beijing, China.
Key people
Lawrence A. Minkoff
Chairman of the Board, President, Principal Executive Officer, Chief Scientific Officer · since 2004
Jerome M. Feldman
Vice President, Independent Director
Kenneth C. Riscica
Treasurer, Secretary · since 2000
Independent Director · since 1998
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑02 | 2018‑02 | 2017‑02 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||